当前位置: X-MOL 学术Int. Immunopharmacol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Prognostic value and immunological role of PDCD1 gene in pan-cancer
International Immunopharmacology ( IF 5.6 ) Pub Date : 2020-10-15 , DOI: 10.1016/j.intimp.2020.107080
Yandong Miao , Jiangtao Wang , Qiutian Li , Wuxia Quan , Yingying Wang , Chen Li , Jingjing Wu , Denghai Mi

Objective

Identify the prognostic value and investigate the association between programmed cell death 1 (PDCD1) gene expression and immune infiltration in pan-cancer.

Methods

We used a series of bioinformatics methods to comprehensively analyze the relationship between PDCD1 gene and prognosis, tumor mutational burden (TMB), microsatellite instability (MSI), immune cell infiltration of various cancers from the existing public database, and try to find the potential prognostic value of PDCD1 for in pan-cancer.

Results

High expression of PDCD1 was closely related to better overall survival (OS) and disease-specific survival (DSS) in breast invasive carcinoma, head and neck squamous cell carcinoma, skin cutaneous melanoma, and uterine corpus endometrial carcinoma; have a better disease-free interval (DFI) and progression-free interval (PFI) in several cancer types. Meanwhile, the high level of PDCD1 gene expression was associated with poorer OS, DSS, and PFI in brain lower grade glioma and uveal melanoma; poorer OS in acute myeloid leukemia and kidney renal papillary cell carcinoma; poorer OS and DSS in glioblastoma multiforme; poorer DSS in kidney renal clear cell carcinoma, by Kaplan-Meier and Cox survival analysis. PDCD1 gene expression was significantly correlated with TMB and MSI in 14 and 12 cancer types, respectively, and infiltrating levels of immune cells, especially Macrophages M0, M1, CD4-T-cells, CD8-T-cells, and T cells follicular helper, in most of eight cancer types.

Conclusion

PDCD1 can be used as a prognostic marker in multiple cancers, owing to it is closely associated with TMB, MSI, and immune cells infiltration.



中文翻译:

PDCD1基因在全癌中的预后价值及其免疫学作用

目的

确定预后价值,并研究程序性细胞死亡1(PDCD1)基因表达与泛癌免疫浸润之间的关联。

方法

我们使用了一系列生物信息学方法从现有的公共数据库中全面分析了PDCD1基因与预后,肿瘤突变负担(TMB),微卫星不稳定性(MSI),免疫细胞浸润之间的关系,并试图寻找潜在的预后泛癌中PDCD1的值。

结果

PDCD1的高表达与乳腺癌,头颈部鳞状细胞癌,皮肤皮肤黑色素瘤和子宫内膜子宫内膜癌的总体生存率(OS)和疾病特异性生存率(DSS)密切相关。在几种癌症类型中,都有更好的无病间隔(DFI)和无进展间隔(PFI)。同时,PDCD1基因的高表达与低级脑胶质瘤和葡萄膜黑色素瘤的OS,DSS和PFI差有关。急性髓细胞性白血病和肾肾乳头状细胞癌的OS较差; 多形胶质母细胞瘤的OS和DSS较差;Kaplan-Meier和Cox生存分析表明,肾透明细胞癌中DSS较差。PDCD1 在14种和12种癌症类型中,基因表达与TMB和MSI显着相关,并与免疫细胞的浸润水平密切相关,特别是巨噬细胞M0,M1,CD4-T细胞,CD8-T细胞和T细胞滤泡辅助细胞。八种癌症中的大多数。

结论

PDCD1与TMB,MSI和免疫细胞浸润密切相关,因此可以用作多种癌症的预后指标。

更新日期:2020-10-16
down
wechat
bug